LY2452473 is an orally bioavailable and selective androgen receptor modulator.

LY2452473 is being developed for the treatment of disorders related to hypogonadism. LY2452473 is absorbed rapidly (time to reach maximum plasma concentration for both LY2452473 and total radioactivity is 2-3 h) and cleared slowly (plasma terminal t1/2 of 27 h for LY2452473 and 51 h for the total radioactivity).

1029692-15-6

C22H22N4O2

374.44

DMSO:62.5 mg/mL (166.92 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years